Literature DB >> 11116070

Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease.

B F Asztalos1, P S Roheim, R L Milani, M Lefevre, J R McNamara, K V Horvath, E J Schaefer.   

Abstract

High density lipoproteins (HDLs) and their subspecies play a role in the development of coronary heart disease (CHD). HDL subpopulations were measured by 2-dimensional nondenaturing gel electrophoresis in 79 male control subjects and 76 male CHD patients to test the hypothesis that greater differences in apolipoprotein (apo)A-I-containing HDL subpopulations would exist between these 2 groups than for traditional lipid levels. In CHD subjects, HDL cholesterol (HDL-C) was lower (-14%, P<0.001), whereas total cholesterol and the low density lipoprotein cholesterol/HDL-C ratio were higher (9% [P:<0.05] and 21% [P:<0.01], respectively) compared with control levels. No significant differences were found for low density lipoprotein cholesterol, triglyceride, and apoA-I levels. In CHD subjects, there were significantly (P:<0.001) lower concentrations of the large lipoprotein (Lp)A-I alpha(1) (-35%), pre-alpha(1) (-50%), pre-alpha(2) (-33%), and pre-alpha(3) (-31%) subpopulations, whereas the concentrations of the small LpA-I/A-II alpha(3) particles were significantly (P:<0.001) higher (20%). Because alpha(1) was decreased more than HDL-C and plasma apoA-I concentrations in CHD subjects, the ratios of HDL-C to alpha(1) and of apoA-I to alpha(1) were significantly (P:<0.001) higher by 36% and 57%, respectively, compared with control values. Subjects with low HDL-C levels (</=35 mg/dL) have different distributions of apoA-I-containing HDL subpopulations than do subjects with normal HDL-C levels (>35 mg/dL). Therefore, we stratified participants according to HDL-C concentrations into low and normal groups. The differences in lipid levels between controls and HDL-C-matched cases substantially decreased; however, the significant differences in HDL subspecies remained. Our research findings support the concept that compared with control subjects, CHD patients not only have HDL deficiency but also have a major rearrangement in the HDL subpopulations with significantly lower alpha(1) and pre-alpha(1-3) (LpA-I) and significantly higher alpha(3) (LpA-I/A-II) particles.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11116070     DOI: 10.1161/01.atv.20.12.2670

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  47 in total

1.  An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice.

Authors:  Shu-Chen Lu; Larissa Atangan; Ki Won Kim; Michelle M Chen; Renee Komorowski; Carolyn Chu; Joon Han; Sylvia Hu; Wei Gu; Murielle Véniant; Minghan Wang
Journal:  J Lipid Res       Date:  2012-01-27       Impact factor: 5.922

2.  Does simultaneous determination of LDL and HDL particle size improve prediction of coronary artery disease risk?

Authors:  Aleksandra Zeljkovic; Vesna Spasojevic-Kalimanovska; Jelena Vekic; Zorana Jelic-Ivanovic; Aleksandra Topic; Natasa Bogavac-Stanojevic; Slavica Spasic; Ana Vujovic; Dimitra Kalimanovska-Ostric
Journal:  Clin Exp Med       Date:  2008-07-11       Impact factor: 3.984

3.  Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1.

Authors:  John T Melchior; Scott E Street; Allison B Andraski; Jeremy D Furtado; Frank M Sacks; Rebecca L Shute; Emily I Greve; Debi K Swertfeger; Hailong Li; Amy S Shah; L Jason Lu; W Sean Davidson
Journal:  J Lipid Res       Date:  2017-05-05       Impact factor: 5.922

4.  Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia.

Authors:  Anu Paranandi; Bela F Asztalos; Alexandra Mangili; Jefferey Kuvin; Jul Gerrior; Heidi Sheehan; Sally C Skinner; Alice M Tang; Christine A Wanke
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08       Impact factor: 2.205

5.  HDL efflux capacity, HDL particle size, and high-risk carotid atherosclerosis in a cohort of asymptomatic older adults: the Chicago Healthy Aging Study.

Authors:  R Kannan Mutharasan; C Shad Thaxton; Jarett Berry; Martha L Daviglus; Chun Yuan; Jie Sun; Colby Ayers; Donald M Lloyd-Jones; John T Wilkins
Journal:  J Lipid Res       Date:  2017-01-03       Impact factor: 5.922

6.  Influence of HDL particles on cell-cholesterol efflux under various pathological conditions.

Authors:  Bela F Asztalos; Katalin V Horvath; Michael Mehan; Yuya Yokota; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2017-04-18       Impact factor: 5.922

7.  High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency.

Authors:  Mariko Tani; Katalin V Horvath; Benoit Lamarche; Patrick Couture; John R Burnett; Ernst J Schaefer; Bela F Asztalos
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

8.  Development of a method to measure preβHDL and αHDL apoA-I enrichment for stable isotopic studies of HDL kinetics.

Authors:  Xuefei Li; Michael Stolinski; A Margot Umpleby
Journal:  Lipids       Date:  2012-08-11       Impact factor: 1.880

9.  Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

Authors:  Bela F Asztalos; Dorothea Collins; Katalin V Horvath; Hanna E Bloomfield; Sander J Robins; Ernst J Schaefer
Journal:  Metabolism       Date:  2008-01       Impact factor: 8.694

10.  Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.

Authors:  Dick C Chan; Gerald F Watts; Esther M M Ooi; Kerry-Anne Rye; Juying Ji; Anthony G Johnson; P Hugh R Barrett
Journal:  Diabetes Care       Date:  2009-08-03       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.